Lori A. Leslie

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Medicine, Hematology, Oncology +8

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal et al. · The Lancet Oncology · 2021 · 617 citations

Medicine, Oncology, Pharmacology +13

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten et al. · New England Journal of Medicine · 2023 · 410 citations · Full text

Medicine, Immunology, Oncology +17

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna et al. · Blood · 2020 · 318 citations · Full text

Pharmacy, Health Sciences, Internal Medicine +3

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Nathan Fowler, Felipe Samaniego, Wojciech Jurczak et al. · Journal of Clinical Oncology · 2021 · 161 citations · Full text

Medicine, Oncology, Pharmacology +13